In line with its 2024-2025 regulatory agenda, Brazil’s drug regulator Anvisa is preparing to establish a regulatory sandbox to bring innovation to patients more quickly. The agency is consulting on a 247-page regulatory impact analysis report with a view to ensuring that the final sandbox model is effective.
The sandbox would aim to address difficulties in regulating the development, manufacturing and commercialization of innovative products and services when...




